Swiss National Bank
PSTX

Swiss National Bank’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Swiss National Bank’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-102,100
Closed -$314K – 2670
2023
Q1 		$314K Buy
+102,100
New +$612K ﹤0.01% 2601

Other funds holding PSTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Swiss National Bank's PSTX Position: Q2 2023 in Review

Swiss National Bank sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q2 2023, closing a stake of 102,100 shares — an estimated $314K sold.

Swiss National Bank first reported a position in PSTX in Q1 2023 and held it in 1 quarter. The position peaked at $314K in Q1 2023. 94 funds tracked by Wall St. Rank hold PSTX as of Q2 2023.

  • Swiss National Bank reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Swiss National Bank sold 102,100 Poseida Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $314K.
  • Swiss National Bank first reported a position in Poseida Therapeutics, Inc. Common Stock in Q1 2023 and held it in 1 quarter.
  • Swiss National Bank's Poseida Therapeutics, Inc. Common Stock position peaked at $314K in Q1 2023.
  • 94 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Swiss National Bank's 13F filing for Q2 2023, filed 9 Aug 2023.